The policy outlook from the Hill
Article Abstract:
A new policy that might force the federal and government to negotiate drug and biologics prices for its Medicare Part D prescription plan is one of the major challenges faced by the Washington DC-based Biotechnology Industry Organization (BIO). The U.S. Food and Drug Administration's (FDA) federal legislation to permit generic or follow-on biologics might reduce the price of biologics.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Action needed to harmonize regulation of low-level presence of biotech traits
Article Abstract:
The rules about the presence of low-level of biotech traits in grains and seed shipments should be synchronized as per the recommendations and regulations of the World Trade Organisation (WTO) for smooth international trade. The need of science-based regulatory system for agricultural products of modern biotech industry is stressed.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The effect of the Private Securities Litigation Reform Act on analyst forecast properties: the impact of firm size and growth opportunities
- Abstracts: Get media relationship input early in planning process. FCC mulls re-write of media ownership laws
- Abstracts: Toll-like receptor therapies compete to reduce side effects. Belated approval of first recombinant protein from animal
- Abstracts: Gold in the ivory tower: Equity rewards of outlicensing. Who took the tech out of biotech? The hermit crab solution
- Abstracts: Building manufacturing capacity - the chapter and verse. Whither agbiotechnology? Fates intertwined